New Research Finds Awareness Low for Ulcerative Colitis Pipeline Drugs

By: Vivisum Partners, LLC
 
RESEARCH TRIANGLE PARK, N.C. - Aug. 17, 2022 - PRLog -- New research into ulcerative colitis pipeline drugs found that US gastroenterologists who treat irritable bowel disease (IBD) have low awareness of some developing therapies.

According to new market analysis published by Vivisum Partners, cobitolimod is the ulcerative colitis pipeline drug with the lowest awareness among healthcare providers (HCPs). In fact, 67% of surveyed gastroenterologists have never heard of cobitolimod. The data can be found in Ulcerative Colitis Clinical Pipeline Analysis, which also contains data showing that some pipeline therapies, such as upadacitinib and filgotinib enjoy much greater recognition among ulcerative colitis drugs in development.

The following list shows the eight ulcerative colitis drugs that Vivisum Partners analyzed in order of highest to lowest awareness among US gastroenterologists:

1.      Upadacitinib
2.      Etrasimod
3.      Filgotinib
4.      Risankizumab
5.      Mirikizumab
6.      Guselkumab
7.      Brazikumab
8.      Cobitolimod

Not all ulcerative colitis pipeline drugs are flying under the radar among US gastroenterologists. Typically, drugs that have already been developed for other indications, especially those approved to treat other immunology and inflammation diseases, enjoy greater awareness among healthcare providers who treat ulcerative colitis. These drugs include Rinvoq (upadacitinib) and Jyselca (filgotinib).

"Drugs with low awareness now, such as Cobitolimod, are gaining some recognition among HCPs for demonstrating better dosing and tolerability compared to the competition," said Elio Evangelista, senior consultant and ulcerative colitis strategist at Vivisum Partners.

Gastros expect Cobitolimod to compete most closely with Zeposia and Xeljanz, both oral treatments for ulcerative colitis. Vivisum Partners' research found that among US gastroenterologists who are most familiar with Cobitolimod, 58% expect it to have better dosing and tolerability compared to competitor brands.

The strategic insights contained in Ulcerative Colitis Clinical Pipeline Analysis, found at http://vivisumpartners.com/reports/ulcerative-colitis-cli..., are designed to guide brand strategy. The market insights in the newly published market research include detailed pipeline product profiles that provide:
  • Impact scores for individual pipeline products
  • New ulcerative colitis drug expectations
  • Pipeline treatment awareness
  • Detailed competitor analysis vs. current in-line brands

ABOUT VIVISUM PARTNERS, LLC

Vivisum Partners, LLC (http://www.vivisumpartners.com) is a market research agency providing strategic marketing consulting and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies and launch successful brands.

End
Email:***@vivisumpartners.com Email Verified
Tags:Ulcerative Colitis
Industry:Biotech
Location:Research Triangle Park - North Carolina - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share